Iti-Nova 200 Capsule contains Itraconazole 200 mg, a broad-spectrum antifungal agent belonging to the triazole class. It is indicated for the treatment of various fungal infections including aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and other systemic and superficial mycoses caused by susceptible fungi. Itraconazole exerts its antifungal effect by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for the synthesis of ergosterol, a key component of fungal cell membranes. This disruption results in increased membrane permeability and ultimately fungal cell death. Iti-Nova 200 Capsule is administered orally and demonstrates good bioavailability when taken with food, enhancing absorption. It is metabolized primarily in the liver via the CYP3A4 pathway and has a relatively long half-life, allowing for once or twice daily dosing depending on the infection severity. Caution is advised in patients with hepatic impairment, congestive heart failure, or those taking concomitant medications that may interact with itraconazole. Common adverse effects include gastrointestinal disturbances, headache, and rash. Regular monitoring of liver function tests is recommended during prolonged therapy. Iti-Nova 200 Capsule should be used under medical supervision to ensure efficacy and safety.